Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease

Experimental and Therapeutic Medicine

Volumn 6, Issue 6, 2013, Pages 1527-1531

  Wang, Weisong ^a   Li, Lihua ^a   Zhou, Zhonghai ^a   Gao, Junjie ^a   Sun, Yinghao ^a  

^a CANGZHOU CENTRAL HOSPITAL   (China)

Author keywords

Aldosterone; Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Chronic glomerular disease; Spironolactone

Indexed keywords

ALDOSTERONE; BENAZEPRIL; LOSARTAN POTASSIUM; SPIRONOLACTONE;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN RESTRICTION; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 84888417195     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1335     Document Type: Article

References (30)

1. Epstein M: Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 37: 677-688, 2001.
2. Hostetter TH, Rosenberg ME, Ibrahim HN and Juknevicius I: Aldosterone in progressive renal disease. Semin Nephrol 21: 573-579, 2001.
3. Nagase M and Fujita T: Aldosterone and glomerular podocyte injury. Clin Exp Nephrol 12: 233-242, 2008.
4. Cravedi P, Brusegan V, Ruggenenti P, Campbell R and Remuzzi G: Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: does it really work? Pharmaceuticals 3: 1-9, 2010.
5. Sato A and Saruta T: Aldosterone escape during angiotensin converting patients enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 29: 13-21, 2001.
6. Sato A, Hayashi K, Naruse M and Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41: 64-68, 2003.
7. Sato A, Saruta T and Funder JW: Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 29: 211-216, 2006.
8. Tang WH, Vagelos RH, Yee YG, et al: Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 39: 70-78, 2002.
9. Schjoedt KJ, Rossing K, Juhl TR, et al: Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68: 2829-2836, 2005.
10. Schjoedt KJ, Rossing K, Juhl TR, et al: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 70: 536-542, 2006.
11. Rachmani R, Slavachevsky I, Amit M, et al: The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study. Diabet Med 21: 471-475, 2004.
12. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F and Parving HH: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study. Diabetes Care 28: 2106-2012, 2005.
13. Praga M, Gutiérrez E, González E, Morales E and Hernández E: Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 14: 1578-1583, 2003.
14. Russo D, Minutolo R, Pisani A, et al: Coadministration of losartan and enalapril exerts additive antiprotennuric in IgA nephropathy. Am J Kidney Dis 38: 18-25, 2001.
15. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
16. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T and Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotension-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361: 117-124, 2003.
17. Struthers AD: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 2: 47-54, 1996.
18. Bomback AS, Kshirsagar AV, Amamoo MA and Klemmer PJ: Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review. Am J Kidney Dis 51: 199-211, 2008.
19. de Zeeuw D, Remuzzi G, Parving HH, et al: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65: 2309-2320, 2004.
20. Jafar TH, Stark PC, Schmid CH, et al: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60: 1131-1140, 2001.
21. Ruggenenti P, Perna A and Remuzzi G: Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 63: 2254-2261, 2003.
22. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K and Hebert LA: Management of glomerular proteinuria: A commentary. J Am Soc Nephrol 14: 3217-3232, 2003.
23. Atkins RC, Briganti EM, Lewis JB, et al: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45: 281-287, 2005.
24. Cha DR, Kang YS, Han SY, et al: Role of Aldosterone in diabetic nephropathy. Nephrology (Carlton) 10 (Suppl): S37-S39, 2005.
25. Han SY, Kim CH, Kim HS, et al: Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17: 1362-1372, 2006.
26. Han KH, Kang YS, Han SY, et al: Spironolatone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 70: 111-120, 2006.
27. Bianchi S, Bigazzi R and Campese VM: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70: 2116-2123, 2006.
28. Sato A, Hayashi K and Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 18: 44-49, 2005.
29. Juurlink DN, Mamdani MM, Lee DS, et al: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543-551, 2004.
30. Struthers A, Krum H and Williams GH: A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 31: 153-158, 2008.